Karuna Faces Investor Suit Over $14B Bristol Myers Buyout
A Karuna Therapeutics Inc. shareholder has filed suit against the Boston-based biotechnology company alleging a proxy statement related to a proposed $14 billion buyout deal between Karuna and Bristol Myers Squibb...To view the full article, register now.
Already a subscriber? Click here to view full article